Untargeted metabolomic study of autism in newborn screening samples: a pilot study.

1

2 Julie Courraud^{1,2}, Madeleine Ernst^{1,2}, Susan Svane Laursen¹, David M. Hougaard^{1,2}, Arieh S. Cohen¹ 3 4 5 ¹ Section for Clinical Mass Spectrometry, Department of Congenital Disorders, Danish Center for 6 Neonatal Screening, Statens Serum Institut Copenhagen, Copenhagen, Denmark 7 ² iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark 8 9 Correspondence: Julie Courraud (julc@ssi.dk), Section for Clinical Mass Spectrometry, Department 10 of Congenital Disorders, Danish Center for Neonatal Screening, Statens Serum Institut, Artillerivei 5, 2300 Copenhagen S, Denmark 11 ORCID 0000-0002-6797-7129 12 13 14 **Abstract:** 15 **Background** The etiopathology of autism spectrum disorder (ASD) is unclear. Main risk factors include both genetic 16 17 and non-genetic factors, especially prenatal and perinatal events. The Danish Neonatal Screening 18 Biobank in connection with registry data provides unique opportunities to study early signs of disease. 19 Therefore, we aimed to study the metabolomic profiles of dried blood spot (DBS) of newborns later 20 diagnosed with ASD. 21 Methods 22 From the iPsych cohort, we randomly selected 37 subjects born in 2005 and diagnosed with ASD in 23 2012 (cases) together with 37 matched controls and submitted their biobanked DBS to an LC-MS/MS-24 based untargeted metabolomics protocol. Raw data were preprocessed using MZmine 2.41.2 and

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

metabolites were subsequently putatively annotated using mzCloud, GNPS feature-based molecular networking and other metabolome mining tools (MolNetEnhancer). Statistical analyses and data visualization included principal coordinates analyses, PERMANOVAs, t-tests, and fold-change analyses. **Results** 4360 mass spectral features were detected, of which 150 could be putatively annotated at a high confidence level. Chemical structure information at a broad level could be retrieved for a total of 1009 metabolites, covering 31 chemical classes including bile acids, various lipids, nucleotides, amino acids, acylcarnitines and steroids. Although the untargeted analysis revealed no clear distinction between cases and controls, 18 compounds repeatedly reported in the ASD literature could be detected in our study and three mass spectral features were found differentially abundant in cases and controls before FDR correction. In addition, our results pinpointed important other factors influencing chemical profiles of newborn DBS samples such as gestational age, age at sampling and month of birth. Limitations Inherent to pilot studies, our sample size was insufficient to reveal metabolic markers of ASD. Nevertheless, we were able to establish an efficient metabolomic data acquisition and analysis pipeline and flag main confounders to be considered in future studies. **Conclusions** In this first untargeted DBS metabolomic study, newborns later diagnosed with ASD did not show a significantly different metabolic profile when compared to controls. Nevertheless, our method covered many metabolites associated with ASD in previous studies, suggesting that biochemical markers of ASD are present at birth and may be monitored during newborn screening. **Keywords:** autism, dried blood spots, untargeted metabolomics, newborn screening, biomarkers

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Background The etiopathology of ASD is still unclear and today ASD is diagnosed based on behavioral signs and assessment of communication skills [1,2]. How the condition should be classified is debated [3,4], as well as which tests offer the most reliable conclusions [1]. In Europe, detection services based on behavioral signs are usually accessed on average at 18 months of age, and diagnosis occurs on average at 36 months of age [5]. In this setting, early intervention is a challenge and has been reported to start in Europe at 42 months of age on average [5]. Whether behavioral impairments are reflected in the blood as biochemical abnormalities is still unsure, but the quest for biomarkers is legitimate, as they would represent a useful tool to help in the diagnosis and treatment of ASD and in understanding its underlying molecular mechanisms [6]. The main risk factors for ASD include genetic [7,8] and non-genetic factors, especially exposure during fetal life [1,9–11]. Prenatal stress could influence fetal brain development and interact with genetic predispositions thereby enhancing the risk of future psychiatric disorders [12,13]. Among prenatal outcomes, maternal infection accompanied by fever during the second trimester of pregnancy has been found to increase the risk of ASD twofold approximately [14]. Among perinatal outcomes, preterm birth (<37 weeks) and low birthweight (small for gestational age) have been associated with an increased risk of ASD as well as high frequency ventilation and intracranial hemorrhage [15]. Low Apgar scores, a score used to summarizing vital signs and assess health in newborns [16], also have recently been associated with an increased risk of developing ASD [17]. Gastrointestinal tract disorders are often reported in ASD children, along with certain foods or diets impacting the severity of symptoms [18–21]. There is a growing evidence of strong interactions

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

between gut and brain through microbiota [22,23], and these observations support the notion that ASD is associated with metabolic malfunction such as decrease in sulphation capacity [18], and potentially connected to gut microbial populations and functions [20]. It has also been shown that many small molecules differing between normally-developing and ASD individuals likely result from microbial metabolism [20,24,25]. Recently, plasma and stool metabolites have been associated with poor communication scoring at age 3, and with good prediction of autism by age 8 [26]. Sharon and collaborators (Sharon et al. 2019) have shown that microbiome and metabolome profiles of mice harboring human microbiota predict that specific bacterial taxa and their metabolites modulate ASD behaviors. They found that taurine and 5-amiovaleric acid (5AV) had significantly lower levels in ASD mice and could show that when feeding BTBR mice either taurine or 5AV, autism-like symptoms such as repetitive behavior and decreased social interaction could be decreased. In an intervention study, treatment with Lactobacillus reuteri has been shown to have beneficial effects on ASD-related social disturbances in mice [27]. In humans, intestinal microbiota transplantation has shown very promising results, both against gastrointestinal tract symptoms and ASD symptoms, granting the therapy a 'fasttrack' status by the FDA [28]. Among the plasma metabolites showing average to good classification capacity between the treated children and the controls, sarcosine, tyramine O-sulfate and inosine 5'monophosphate were selected as most discriminant [29]. Many of these studies postulate that microbiota-derived molecules are transported across the blood-brain-barrier, acting as neuroactive metabolites [22]. An impaired intestinal permeability or 'leaky gut' could also play a role in the effect of microbiota activity on psychiatric disorders [30,31]. If gut microbial metabolites of potential impact are indeed detectable in blood, this opens the door to blood-based investigations to further study and understand the metabolomic differences between ASD and non-ASD individuals in the context of gutbrain interactions.

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Several studies have reported an altered metabolome associated with ASD during childhood, either in blood [32–35,25,36–44], urine [18,38,45–56] or other matrices [25,57]. However, although some biochemical biomarkers or set of biomarkers seem promising [6], none has yet been proven robust enough for clinical practice. Furthermore, it remains unclear at what point in life biochemical abnormalities of ASD are detectable. To study the early role of genetic, prenatal and perinatal variables on disease development, samples need to be collected shortly after birth. However, it is not practically and ethically straightforward to draw blood from newborns prospectively. In many countries, the newborn screening programs are conducted on dried blood spots (DBS) collected a few days after birth. In Denmark, such DBS are stored in the Danish National Biobank and are available for research purposes for the last 30 years, thereby covering approximately half of the country's population [58]. This allows researchers to alleviate the biases inherent to recruitment in prospective clinical studies and instead retrospectively retrieve the samples that are connected to the relevant metadata stored in centralized health registries. Taking advantage of this unique resource, we here aimed at studying the strengths and limitations of DBS samples in studying early biochemical abnormalities related to ASD development using an untargeted metabolomics protocol. We compared the metabolomic profiles of newborns that have been diagnosed with ASD at age 7 (cases) to newborns that have not (controls) and investigated potential main confounders. Methods Materials and methods Materials

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

Methanol (MeOH), acetonitrile (ACN), isopropanol (IPA), water (H₂O) and formic acid (FA) were of OptimaTM LCMS-grade and were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Stable-isotope-labeled internal standards (IS) from the NeoBase Non-derivatized MSMS kit (PerkinElmer, Waltham, MA, USA) were used. The exact list of compounds is provided in Additional file 1. Subjects and samples Children (n=74) from the iPsych cohort [59] born in 2005 were randomly selected, of which 37 with a diagnosis of autism spectrum disorder (ICD10 F84.0, F84.1, F84.5, F84.8 and/or F84.9) [2] at the date of registry data extraction (2012), and 37 paired controls. Cases and controls were matched based on gender and date of birth. Other metadata such as gestational age (GA), birthweight, age at sampling, month of birth, mother's age at birth, and date of diagnosis, were also collected (when available). Sample size was chosen for several reasons: 1) the unknown variation of metabolites in DBS made power calculations impossible, hence why we needed a pilot study, 2) batch effect is a common technical challenge in metabolomics, and analyzing all samples on one single 96-well plate was expected to reduce technical variability, 3) DBS are highly precious samples. DBS are full blood from newborns, aged between 48 and 72 hours, blotted onto Ahlstrom #226 filter paper and left to dry for at least 3 hours at room temperature before being sent by mail at ambient temperature to the Department of Congenital Disorders at the Statens Serum Institut in Copenhagen. Subsequent to being used in the newborn screening program the samples are biobanked in the Danish National Biobank (www.nationalbiobank.dk) at -20°C until they are retrieved for further research analysis. Sample extraction

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

A punch of 3.2-mm diameter was collected from each DBS using a Panthera-PuncherTM 9 blood spot punching system (PerkinElmer) directly into a MicroPlate, non-coated 96-well clear polystyrene plate (PerkinElmer). 100 µL of IS in extraction buffer were added to each well. The IS were labelled amino acids (AA IS) and acylcarnitines (AC IS) diluted in 80% methanol (i.e. dilution factor of 1:330, concentrations in Additional file 1). The plate was heat-sealed and shaken for 45 min at 750 rpm at 25°C in a PHMP-4 incubator. Then it was centrifuged for 30 min at 4000 rpm at 4°C. All the transferring steps were performed on a Microlab STAR line automated liquid handling workstation using Venus software (Hamilton, Bonaduz, Switzerland). The supernatant (75 μL) was transferred to a hard-shell 96-well polypropylene PCR plate (Bio-Rad) and dried down with nitrogen 60 L/min at 25 °C for 1 hour on an EVX-192 (Apricot Designs Evaporex). The residue was reconstituted in 75 µL 2.5% methanol, shaken for 15 min at 750 rpm at 25°C in a PHMP-4 incubator, and centrifuged 10 min at 4000 rpm at 4 °C. 65µL were transferred to a hard-shell 96-well polypropylene PCR plate (Bio-Rad), heat-sealed, and centrifuged again for 5 min at 3000 rpm at 4 °C. The method from sample preparation to MS acquisition is also available as a table according to the guidelines for standardization of LCMS method reporting [60] with adaptation to metabolomics (Additional file 1). Quality assurance LC-MS/MS instrument performance was controlled by analyzing 4 pooled extracts, 8 solvent blanks, and 3 paper blanks at regular intervals. Pooled extracts were made of 5 µL of reconstituted extract from each of the samples (cases and controls only, total of 370 µL divided in four wells spread across the plate) and were used to assess the consistency of extraction and data acquisition. Solvent blanks were used to check for carry over and instrument noise, while paper blanks were used to monitor matrix signals from the paper. Internal standards were used to control the quality of the extraction, elution, and

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

signal acquisition. Paired cases and controls were injected after one another but in a random order (first case, then control, or vice-versa). Pairs were randomized over the plate. Liquid chromatography The samples were injected using an autosampler with stack cooler (Open Autosampler UltiMate OAS-3300TXRS (Thermo Fisher Scientific)) and eluted through a Waters Acquity UPLC BEH C18 column (130 Å, 2.1 mm x 50 mm, 1.7-µm particles) preceded by a Waters Acquity UPLC BEH C18 VanGuard pre-column, 130 Å, 2.1 mm x 5 mm, 1.7-µm particles) using a Transcend II, LX-2 with UltiMate pumps (Thermo Fisher Scientific). The pressure limits were set at 0.0 - 1034.0 bar. The mobile phase consisted of solvent A (97.31% H₂O, 1.25% ACN, 1.25% MeOH and 0.2% FA), and B (2.49% H₂O, 48.66% ACN, 48.66% MeOH and 0.2% FA). The Wash1 solvent was mobile phase A and the Wash2 solvent mix was 25:25:25:25 v/v MeOH:IPA:H₂0:ACN + 0.2% FA. The gradient (0.25 mL/min) started with 100% A: 0% B. After 0.5 min, we applied a gradient ramp to 0% A: 100% B over 8.5 minutes followed by a 0.5-min flow ramp up to 0.9 mL/min and 5 minutes of 100% B. At 15 min, the column was equilibrated for 5.5 min with 100% A. At 17.5 min, the flow was changed back to 0.25 mL/min over 0.5 min. The total run time was 20.5 minutes, including 10 min sample run time and 10.5 min column wash and equilibration. The column temperature was maintained at 60.0°C using a hot pocket column heater and the samples in the autosampler were kept at 4°C throughout the analysis. The data was acquired in profile mode from 0.20 min and over 9.80 min. *Mass spectrometry*

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

The O-Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific) was operated with a heated electrospray ionization source (HESI) in positive mode. The instruments were controlled using TraceFinder 4.1 Clinical Research and Aria MX (Thermo Fisher Scientific). Mass range in MS full scan mode was set to 70 to $1050 \, m/z$ with a resolution of 35,000. Automatic gain control was set to 1.10⁶, and maximum injection time at 100 ms. For data dependent-MS2 the resolution was set to 17,500. Automatic gain control was set to 1.10⁵, and maximum injection time at 50 ms. Loop count was 5, isolation window 1.5 m/z and the stepped NCE 17.5, 35 and 52.5 eV. The spectrum data type was set to Profile. In data dependent settings the Apex trigger was set to 2 to 7 s with 15s dynamic exclusion and charge exclusion on 3-8 and >8. Diisooctylphtalate $(391.28429 \, m/z)$ was selected as lock mass. Other settings included the sheath gas pressure (N₂, 32 psi), the auxiliary gas flow and temperature (N₂, 8 arb. units, 350°C), the S-lens radio frequency level (50.0%), the ion source temperature (350°C), and the spray voltage (3.8 kV between 0-9.8 min and 1.0 kV between 9.8-10 min). LC-MS data preprocessing After conversion to .mzML (centroid) using MSConvertGUI v3.0 (ProteoWizard Software Foundation, Palo Alto, CA, USA) [61], raw files were pre-processed using MZmine v2.41.2 [62,63]. All setting details are provided in the batch .xml file (Additional file 2). Briefly, data were cropped based on retention time (RT) 0.27-9.80 min. Masses were detected with a noise threshold of 10,000 for MS1 and of 0 for MS2. The chromatogram was built using the ADAP module [64], with minimum 7 scans per peak, a group intensity threshold of 10,000, a minimum highest intensity of 150,000, and a m/ztolerance of 0.001 m/z or 5 ppm. Deconvolution was performed using the Wavelets (ADAP) module, with m/z center calculation using median, and ranges for MS2 scan pairing of 0.01 Da and 0.4 min. The

isotopes were grouped with a m/z tolerance of 0.001 m/z or 5 ppm and RT tolerance of 0.1 min. Peaks

were aligned with a m/z tolerance of 0.001 m/z or 5 ppm and RT tolerance of 0.1 min, with 75% weight given to m/z and 25% to RT. Finally, peaks were filtered with a minimum of fifteen peaks in a row, and the same RT and peak duration ranges as previously applied. The feature quantification table (.csv) and aggregated MS2 masses list (.mgf) were exported (no merging of MS/MS and filter rows: ALL) for further analysis.

Feature-based molecular networking using GNPS and compound annotation

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

A molecular network was created with the feature-based molecular networking workflow (https://ccmsucsd.github.io/GNPSDocumentation/featurebasedmolecularnetworking/) [65] on the GNPS website (http://gnps.ucsd.edu) [66] by uploading the aggregated MS2 mass list. The data was filtered by removing all MS/MS fragment ions within +/- 17 Da of the precursor m/z. MS/MS spectra were window filtered by choosing only the top 6 fragment ions in the +/- 50Da window throughout the spectrum. The precursor ion mass tolerance was set to 0.02 Da and a MS/MS fragment ion tolerance of 0.02 Da. A network was then created where edges were filtered to have a cosine score above 0.7 and more than 4 matched peaks. Further, edges between two nodes were kept in the network if and only if each of the nodes appeared in each other's respective top 10 most similar nodes. Finally, the maximum size of a molecular family was set to 100, and the lowest scoring edges were removed from molecular families until the molecular family size was below this threshold. The spectra in the network were then searched against GNPS' spectral libraries. The library spectra were filtered in the same manner as the input data. All matches kept between network spectra and library spectra were required to have a score above 0.7 and at least 4 matched peaks. The .graphml network file was then visualized using Cytoscape v3.7.2 [67] where individual sample data and metadata were locally plotted (per sample and metadata sample group relative intensities). To enhance annotation of potential compounds of interest using the mzCloud spectral library (Thermo Fisher Scientific), .raw files were also preprocessed using Compound Discoverer 2.1 (CD2.1) SP1 software

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

(Thermo Fisher Scientific). Details regarding the settings are provided in Additional file 3. GNPS and Compound Discoverer (annotation reported when above mzCloud 80% confidence in identity or similarity search) offer annotations with a level 2 confidence according to the Metabolomics Standards Initiative (i.e. putative annotation) [68,69]. To summarize and further enhance chemical structural information within the molecular network. substructure information (https: //ccmsucsd.github.io/GNPSDocumentation/ms2lda/) [70], information from in silico structure annotations from Network Annotation Propagation [71] and Dereplicator [72] were incorporated using the GNPS MolNetEnhancer workflow (https://ccms-ucsd.github.io/GNPSDocumentation/molnetenhancer/) [73] with chemical class annotations retrieved from the ClassyFire chemical ontology [74]. When no chemical structural information could be retrieved through the above searches, the MS/MS spectra were additionally searched via MASST [75] and SIRIUS+CSI:FingerID [76–78]. MASST allows to query a single MS/MS spectrum across all public GNPS datasets giving an idea of the type of samples or matrices where the same MS/MS spectrum has been detected [75]. SIRIUS+CSI:FingerID uses deep learning algorithms to predict the molecular and structural formula of a molecule from MS/MS spectra [76–79]. Contamination filtering and further data curation Using a Kendrick Mass Filter, we explored the compositionality of our data to assess the potential presence of undesired chemical background [80]. Out of the 4,360 features obtained through MZmine preprocessing, more than 1,100 possessed repeat units typical of polyethylene glycol (PEG) and polypropylene glycol (PPG). Filtering of PEG followed by filtering of PPG was performed using a Kendrick Mass Filter [80] with the following parameters: number of observed signals = 5, Kendrick mass defect = 0.01, and fraction base = 1 (see Additional file 4AB).

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

Of the 3,253 remaining features, we further excluded those with a maximum intensity in paper blanks / maximum intensity in samples ratio > 0.2, as well as features with 20% or more gaps (i.e. missing value) in cases and/or in controls (1,975 features filtered). Data visualization and outlier handling We performed principal coordinates analyses (PCoA) to visualize the data in an interactive 3D-space using EMPeror within QIIME 2 [81,82] using the Bray-Curtis, Canberra, Robust Aitchison [83] and Jaccard distance metrics. This tool allowed us to easily map metadata on each sample in the 3D-space and quickly detect broad patterns in the data, such as assessing the consistency of repeated pool injections (i.e. repeated injections of the same pooled samples should cluster in PCoA space). When performing these calculations on our "raw" unfiltered feature table (4,360 features), all tested distance metrics showed seven samples as clear outliers, of which two controls and five cases. After contamination filtering and data curation (1,281 features), six outliers remained since one outlier (control) was due to PEG contamination. Among the investigated potential explanations for these outliers, no pattern was found when looking at: position on the plate layout, potential RT shift impairing the alignment, and metadata. However, targeted analysis of labeled internal standards and unlabeled endogenous homologs showed that significant (but unexplained) errors occurred during LCMS acquisition, with many undetectable compounds (TraceFinder 4.1 Clinical Research, Thermo Fischer Scientific) (Additional file 5). A heatmap representation of the data (1,281 features) using MetaboAnalyst 4.0 [84] confirmed the six outliers with very low intensities (Additional file 5). Therefore, we decided to exclude these outliers from further statistical analyses and reran the PCoA calculations on the remaining 68 samples. **Statistics**

Using the calculated distance matrices from the PCoAs (1,281 features, 68 samples), we performed Permutational Multivariate Analyses of Variance (PERMANOVAs) [85] to assess how much of the variance in the data is explained by a certain variable in the metadata. We investigated the following variables: autism (yes/no), autism subtype, gender, birthweight, gestational age, age at sampling, month of birth, and injection order. The Adonis R² value indicates to what extent the variance is explained by the tested variable. Significance threshold was set at 0.05. Calculations were performed using the *vegan* and ggplot2 packages in R software v3.6.1 [86]. Finally, the curated dataset (1,281 features, 68 samples, unpaired samples) was processed using MetaboAnalyst 4.0 [84]. We excluded features with more than 50% missing values and replaced the remaining missing values by a small value (half the minimum positive value in the original data). We further filtered non-informative near-constant features based on interquantile range and applied a glog transformation and Pareto scaling. We used a fold-change threshold of 2 (case/control or control/case) and performed t-test and Wilcoxon rank-sum test with FDR correction for multiple comparisons. We could not reliably use the Partial Least Squares Discriminant Analysis (negative Q2 in cross validation). All Jupyter notebooks used for statistical analysis are publicly available on github (https://github.com/madeleineernst/Autism_SupplementaryMaterial).

Results

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

Subjects

Subjects' characteristics are presented in Table 1 (details in Additional file 6). Cases and controls were similar in terms of GA, birthweight, age at sampling and age of their mother at birth. The most prevalent autism subtype was childhood autism. Most cases had only one diagnosis, but six had both unspecified pervasive development disorder and autism (either childhood autism or atypical autism).

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

None had more than two diagnoses. Median age at first diagnosis was 5.6 years (range 1.1-7.8). Most subjects were born at term (GA > 38 weeks). Only three cases and two controls were born preterm. [Table 1] Molecular Network analysis From all features for which a MS2 spectrum has been acquired (2217 features over 4360) a featurebased molecular network was computed via GNPS. Annotation could be retrieved for 150 features (3.4%) of which 103 by matching to GNPS libraries (annotation level 2), and 47 by matching to our inhouse library using Trace Finder (annotation level 1, Additional file 7). Using the MolNetEnhancer workflow [73], putative chemical structural information at the chemical class level, corresponding to a level 3 annotation, could be retrieved for an additional 859 features. Hence, nearly 46% (1009) of the mass spectral features could be putatively annotated at a level 1 to 3 (Additional file 7). Annotation covered 31 chemical classes including 53 subclasses and 116 direct parents, such as medium-chain fatty acids, phosphatidylcholines, nucleotides, amino acids, bile acids, steroids, acyl carnitines and catecholamines. Molecular families (independent clusters of nodes) from the 15 predominant putatively annotated chemical classes are presented in Figure 1 (see details in Additional file 7). Plotting the average intensities in the three groups (cases, controls, paper blanks) as well as fold change values (or p-values) on the network nodes allowed for a quick overview of the molecular families with potential biological relevance (See the example of bile acids in Figure 2). This analysis showed the potential of DBS in covering various chemical classes and the power of feature-based molecular network analyses and related metabolome mining tools in expanding the interpretability of complex untargeted metabolomics data.

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

Statistical analyses In PCoA space, repeated pool injections clustered satisfactorily showing that the LC-MS/MS data acquisition was of acceptable quality (Figure 3). When looking at the two groups (cases/controls), no clear separation was observed, even after removal of outliers (Figure 3A) and on all tested distance metrics. The PERMANOVAs (Figure 4, Additional file 8) revealed that the variance in the data was not significantly explained by the grouping (cases/controls) (Bray-Curtis Adonis $R^2 = 0.014$, P-value = 0.777), even when distinguishing subtypes of ASD, although subtypes had a higher Adonis R² (Bray-Curtis Adonis $R^2 = 0.070$, P-value = 0.707, see Table 1 for details on subtypes of ASD). Similarly, the gender and birthweight did not significantly explain the variance in the data. However, variation in the data explained by gestational age (Bray-Curtis Adonis $R^2 = 0.034$, P-value = 0.028), age at sampling (Bray-Curtis Adonis $R^2 = 0.053$, P-value = 0.002) and especially month of birth (Bray-Curtis Adonis $R^2 = 0.262$, P-value = 0.001, see Figure 3B) was significant, and to an increasing extent respectively (greater Adonis R²). On a technical level, we also observed a significant effect of injection order on the data variation (Bray-Curtis Adonis $R^2 = 0.047$, P-value = 0.002), pointing to a limitation in our LC-MS/MS method. Results of univariate analyses and fold change analysis were carefully scrutinized feature by feature. Considering our small sample size and potential pitfalls inherent to untargeted metabolomics related to contaminants or integration errors, we thought essential to inspect each result to eliminate false positives and spurious findings. Our inspection consisted of a five-step logic starting with peak integration and shape quality (MZmine). We then plotted all individual intensity values to assess whether the case/control difference was driven by four or fewer samples. If not, we reported the extent

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

of missing values in each group, checked the consistency of replicated pool injections, and finally checked whether the feature was present in the feature-based molecular network, annotated as a contaminant or in a node cluster with such annotation (Additional file 9). A large proportion of the inspected features were excluded based on these criteria, showing the importance of such a verification in order not to pursue spurious findings in future studies. Among the 24 features with a fold change (case/control) value <0.5 or >2.0, only one passed manual inspection (Table 2, the full table is in Additional file 9). Eluting quite late (RT = 6.64 min, ID8605), this relatively hydrophobic compound had a detected m/z of 1014.4892 and was not connected to any other node in the network analysis (see its mass spectrum in Additional file 10). It could not be annotated, but the algorithm of SIRIUS+CSI: FingerID pointed at a raw formula of C₃₆H₆₃N₂₁O₁₄ ([M+H]+, only 7.12% scoring). This compound was more than twice as intense in controls as in cases (FC 0.42, average intensity in cases 2.73E+05 and controls 7.51E+05), and would need further investigation, especially as it was not detected in many samples (Additional file 9). A MASST search was performed, however the feature with m/z 1014.4892 was not found in any of the public datasets on GNPS. [Table 2] No feature was significantly differentially abundant in cases and controls according to the univariate analyses with FDR correction for multiple comparisons (p values in Table 2). Features that were differentially abundant before FDR correction are presented in Table 2. As a high proportion of features were deemed irrelevant after inspection, we are presenting only the two relevant features that passed our quality-control criteria. The full list and inspection details can be found in Additional file 9. Methacholine was found to be significantly more abundant in cases when compared

to controls (average intensity in cases 4.41E+07 and controls 3.94E+07) both when using a t-test (p = 0.0021) and a Wilcoxon rank-sum test (p = 0.0031). The corresponding node (ID159) in the network analysis was connected to another node with a mass difference of -0.036 m/z (225 ppm) which could not be annotated. None of the applied metabolome mining tools was able to retrieve chemical structural information for the second compound significantly more abundant in cases than in controls (ID5593, m/z 1014.4892, average intensity in cases 5.71E+05 and controls 4.35E+05). SIRIUS+CSI:Finger ID predicted a molecular formula of $C_{11}H_{22}N_2O_3$ (M+H+, 99.96% scoring). Its RT of 2.78 min could indicate a medium polarity with a logP between -1.0 and 0.5 when compared to tryptophan (RT 2.56 min, HMDB experimental logP -1.06) and hippuric acid (RT 3.04 min, HMDB experimental logP 0.31).

Among the 273 compounds reported in two recent reviews [6,87], 22 were cited at least three times, of which 18 could be linked to features in our study after manual verification (Table 3, Additional file 11).

Discussion

To assess the early signs of ASD development shortly after birth, we compared DBS samples from newborns that have later on been diagnosed with ASD to newborns that have not. Our pilot study showed the capacity of untargeted metabolomics as an analytical tool applied to biobanked DBS samples to cover several metabolites relevant to ASD, thus suggesting that biochemical markers of ASD are present at birth and could be targeted during neonatal screening. In addition, our method pinpointed other factors which have a strong influence on the metabolic profile of newborn DBS, such

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

as gestational age, age at sampling and month of birth, and which are important to consider when designing metabolomic studies in neonatal, biobanked DBS. One study from 2013 was performed on newborn DBS samples from 16 autistic children and assessed 90 biomarkers (not only small molecules) using immunoassays [88] of which three sets of five were associated with ASD. Another study was performed on DBS but in ASD children (n=83, age 2-10 years) and was targeting 45 metabolites [37], of which 9 were significantly higher in ASD children. However, the potential of DBS in *untargeted* metabolomics studies has not yet been fully studied, and never in the context of ASD (see recent reviews [6,87]). Among the 22 compounds that had been repeatedly (≥3 times) reported in the literature to be involved in ASD, 18 could be putatively annotated in our study, showing that our analytical pipeline covers many relevant metabolites, including some specific to gut microbiota activity. Despite thorough curation and inspection of the acquired data, no feature was significantly differentially abundant in cases and controls after FDR correction. The small sample size as well as strong confounders could play a role in the low power of this pilot study. Nonetheless, the PERMANOVA results showed that subtypes of autism seemed to explain more variance in the data than just the case/control division (higher Adonis R², Figure 4). This could mean that subtypes have indeed distinct biochemical profiles and should maybe be considered separately or in a stratified manner. Although, the lack of significance could suggest that ASD genetic, prenatal and/or perinatal variables do not (sufficiently) translate into biochemical abnormalities in newborns or that these are not detectable in biobanked DBS using our current experimental setup, we were able to pinpoint 18 out of 22 metabolic markers associated with ASD in previous studies. This finding suggests that rather the sample size and confounders are responsible for the absent signal observed here, and future studies controlling for the here identified confounders and greater sample size could provide more answers.

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

Among the hits and interesting findings of our pilot, we could show that a methacholine structural analogue could be a relevant marker for ASD, as it was found at a higher although not significant abundance in newborns that have been diagnosed with ASD at age 7. Methacholine is a choline ester drug acting as non-selective muscarinic receptor agonist. It is mainly known as methacholine chloride for its use in assessing bronchial hyper-reactivity in asthmatic patients. Although muscarinic receptors were not associated with autism in children [89], lower estimates of ASD risk among children exposed during fetal life to muscarinic receptor 2 agonists were reported [90]. Higher abundance of methacholine in DBS of ASD cases, as seen in our study, would therefore not be easily explained and demand further investigation. However, detecting a drug metabolite such as methacholine in newborn samples is unexpected, thus it is more likely that this feature is an endogenous choline ester with similar fragmentation behavior to methacholine. Two other unknown features would benefit from being monitored in future studies. One relatively hydrophobic compound (ID8605, m/z 1014.4892) showed an important fold change (much lower in cases) but was not detected in many samples maybe due to low intensities. The second compound (moderately polar, ID5593, m/z 1014.4892, $C_{11}H_{22}N_2O_3$) was significantly higher in cases before FDR correction and detected in more than 65% of samples. Including both in an inclusion list for optimized MS2 acquisition could provide higher quality spectra for better annotation. Overall, we observed poor fragmentation of some analytes (4 fragmentation peaks or less) and optimization of fragmentation parameters to a few targeted compounds, could enable better chemical structural annotation, although fragmentation parameters such as other technical and sample preparation parameters, can never be optimized for all compounds equally.

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

Although our study was not designed specifically to assess the tested confounders, we have shown that gestational age, age at sampling and month of birth are strong drivers of metabolomic profiles in newborns. This demonstrates the importance of considering these confounders when designing a future study in newborn DBS. Prematurity has been involved in numerous adverse health outcomes [91] and metabolic maturity has been shown to be reflected in the blood and other matrices of infants after birth [92,93]. Although, in the present study, only three cases and two controls were premature (<38 weeks of gestational age), we saw a significant effect of gestational age on the metabolomic profile of newborns thus showing that gestational age is an important factor be controlled for in newborn DBS studies. Similarly, we found that age at sampling has a significant impact on the newborn blood metabolome. From 3 to 10 days of age, only one week has passed, and yet fundamental metabolic changes occur in the newborn who is not anymore connected to his/her mother's blood, but exposed to various types of nutrition and environmental conditions (healthcare, hospital vs home, etc.). The endogenous anabolism/catabolism balance is in itself a strong variable to consider at that age. From 2009 onwards, the Danish newborn screening program has indeed chosen to standardize the age at DBS sampling to 48 to 72 hours to optimize the window where potential inborn errors of metabolism would be detected best and as early as possible since quick intervention is essential in such cases [94]. The iPsych cohort was based on diagnoses of psychiatric disorders recorded in Danish health registry in 2012 [59]. Such diagnoses are often given after several years of age, which is why the cohort did not cover subjects born after 2005, year at which the age at sampling was not so narrowly standardized. The large sample size of the iPsych cohort (almost 15,000 cases of ASD) should however allow for stricter selection criteria in our future studies.

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

Another major change that occurs in newborns at birth and in the following days is the gut maturation and its further colonization by microbes [95]. This topic has been under expanding attention in the last decade, and the development and involvement of gut microbiota in neurodevelopment is being scrutinized extensively [22]. The exact dynamics of the microbiota development in the placenta and during the first days of life is still uncertain [95–97], as well as to what extent its activity can be reflected in the blood. A recent study has shown that gut microbial alpha-diversity can be predicted from the human blood metabolome [98] suggesting that microbial metabolites explain a significant amount of the variance in the human blood metabolome. Thus, although sampled at an early stage in life, it is plausible that microbial metabolites mediating health may be found in dried blood spots from newborns [93]. Studying both fecal and blood samples will be essential to answer questions related to the impact of gut microbes on the gut-brain axis, especially in the context of psychiatric disorders where the brain is the main organ concerned but indeed located quite far from the gut. Microbial metabolites would necessarily need to travel in the blood (or lymph) and through the blood-brain barrier to interact with the brain. In our study, some detected metabolites could partly derive from gut microbiota activity such as DL-Indole-3-lactic acid (ID3461, [99,100]), taurine (ID428, level 3, [25]), various bile acids (Additional file 7, [57]), or inosine 5'-monophosphate (ID1133, level 3, [29]). Lastly, we found that month of birth explains a significant variation in metabolomic profiles of newborns (Figure 3b, Figure 4). Whether there is a yearly cyclic pattern or whether our findings are specific to 2005 remains to be determined. Explanations could include aspects related to pregnancy conditions varying along the year such as diet, weather conditions and sun exposure (e.g. impact on vitamin D levels, type and extent of physical and social activities, mood and stress [101]), exposure to

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

"seasonal" infectious diseases (e.g. influenza), exposure to varying air quality (e.g. pollution or pollens [102]), as well as storing conditions which might fluctuate over the year (e.g. sample transport at higher temperatures during summer). Gender and birthweight were not found to explain a significant part of the variance in the metabolomic profiles of newborns in our study, despite the obvious connection between gestational age and birthweight. The gender misbalance which reflects the gender disparity in ASD (a quarter were girls), non-dedicated design, and small sample size could explain this finding. Some studies have indeed reported that the profile of newborn girls and boys differed in, for instance, blood amino acids and acylcarnitines [103], as well as urine profiles [104]. Despite our finding, we believe that gender and birthweight should be adjusted for and taken into consideration when designing metabolomics studies in newborns. Several of the tested confounders are inter-connected with, for instance, reports of more males being born preterm [105] and females being born lighter [106], both associations being explained by mechanisms that are likely to be reflected in the metabolome such as inflammatory response and insulin resistance, respectively. On the technical side, the strong effect of injection order is again a reminder that randomizing sample pairs on the plates is fundamental in untargeted metabolomics. Although technical improvements can be considered, it is extremely difficult if not impossible to avoid some level of signal drift and carryover in untargeted metabolomics studies[107]. **Limitations and strengths** To avoid batch effect and minimize the use of highly valuable and rare samples, we analyzed only 37 pairs of cases and controls in this pilot study. Despite the small sample size that did not confer enough

statistical power for pinpointing strong marker metabolites of ASD, we could detect numerous metabolites associated with ASD in previous studies and identify a number of confounders to be considered in future untargeted metabolomics study using newborn DBS. Other confounders not evaluated in our study will need to be assessed in future studies, including metabolic changes in DBS associated with time and storage conditions. Hematocrit variation could not be measured in our study as we had access to only one punch of paper and did not have the possibility to measure a surrogate marker such as potassium [108]. Furthermore, metabolites detected in this study are inherently reflective of sampling protocols, including extraction protocols and MS acquisition parameters and should be interpreted within these limitations.

Conclusions

This is the first study assessing metabolomic profiles of a psychiatric disorder, ASD in biobanked, newborn DBS samples. The development of biobanks and reuse of systematically collected DBS samples for research purposes in connection with registry data represent many new opportunities to study the physiopathology and early signs of diseases, with extraordinary impacts in prevention, diagnosis and treatment strategies. We showed that untargeted metabolomics on DBS samples offers a wide and relevant coverage of metabolites for the study of ASD and that the new processing tools used in our method largely expand the interpretability of such complex data.

Declarations

• Ethics approval and consent to participate

The Danish ethical committee approved the project (1-10-72-287-12). All blood samples can be stored without explicit informed consent according to Danish law, and be reused for additional analysis

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

provided that projects are approved by the Research Ethics Committee and the Danish Data Protection Agency. Although research projects require informed consent, the Research Ethics Committee can waive this requirement if samples are anonymously processed, and if the projects do not imply any health-related risk or burden to the subjects [109]. Consent for publication Not applicable Availability of data and materials The datasets generated and/or analyzed during the current study are not publicly available due to the risk of compromising individual privacy but are available from the corresponding author on reasonable request and provided that an appropriate collaboration agreement can be agreed upon. Competing interests The authors declare that they have no competing interests. **Funding** This study was funded by The Lundbeck Foundation, Denmark. This research has been conducted using the Danish National Biobank resource supported by the Novo Nordisk Foundation grant number is 2010-11-12 and 2009-07-28. Disclaimer This funder had no involvement in any aspect of the study.

569 Grant number

573

584

588

591

592

- 570 R248-2017-2003 Period III: 1 March 2018 28 February 2021
- 571 R155-2014-1724: Period II: 1 March 2015 28 February 2018
- 572 R102-A9118: Period I: 1 March 2012 28 February 2015
- Authors' contributions
- 575 JC and AC designed the study.
- 576 SSL collected the samples and ran the metabolomics analyses.
- 577 ME defined and coded major steps of data processing, chemical structural annotation and statistical
- analysis and edited the manuscript.
- 579 JC processed the data, performed statistical analyses, and drafted the manuscript.
- 580 JC, ME, SSL and AC were involved in the manuscript edition and data interpretation, critically revised
- the manuscript for important intellectual content, and approved the final version of this manuscript.
- JC and AC had full access to all the data in the study and take responsibility for the integrity of the data
- and the accuracy of the data analysis.
- Acknowledgements
- We thank Anders Björkbom for his major contribution to the LCMS method development and Marie
- 587 Bækvad-Hansen for her help in curating data.
- Authors' information (optional)
- Not applicable
- 593 References
- 1. Randall M, Egberts KJ, Samtani A, Scholten RJ, Hooft L, Livingstone N, et al. Diagnostic tests for autism
- 595 spectrum disorder (ASD) in preschool children. Cochrane Database Syst Rev. 2018;
- 596 2. World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria
- for research. Geneva: World Health Organization; 1993.
- 3. Adam D. Mental health: On the spectrum. Nat News. 2013;496:416.
- 599 4. Frances A. ICD, DSM and The Tower of Babel, Aust N Z J Psychiatry, 2014;48:371–3.

- 5. Bejarano-Martín Á, Canal-Bedia R, Magán-Maganto M, Fernández-Álvarez C, Cilleros-Martín MV, Sánchez-
- 601 Gómez MC, et al. Early Detection, Diagnosis and Intervention Services for Young Children with Autism
- Spectrum Disorder in the European Union (ASDEU): Family and Professional Perspectives. J Autism Dev
- 603 Disord. 2019;
- 6. Shen L, Liu X, Zhang H, Lin J, Feng C, Iqbal J. Biomarkers in autism spectrum disorders: Current progress.
- 605 Clin Chim Acta Int J Clin Chem. 2019;502:41–54.
- 7. Bai D, Yip BHK, Windham GC, Sourander A, Francis R, Yoffe R, et al. Association of Genetic and
- 607 Environmental Factors With Autism in a 5-Country Cohort. JAMA Psychiatry. 2019;76:1035–43.
- 8. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk
- ovariants for autism spectrum disorder. Nat Genet. 2019;51:431–44.
- 9. Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, Levy SE, et al. The epidemiology of autism
- spectrum disorders. Annu Rev Public Health. 2007;28:235–58.
- 612 10. Hannon E, Schendel D, Ladd-Acosta C, Grove J, Hansen CS, Andrews SV, et al. Elevated polygenic burden
- for autism is associated with differential DNA methylation at birth. Genome Med. 2018;10.
- 11. Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low maternal melatonin level increases autism
- spectrum disorder risk in children. Res Dev Disabil. 2018;82:79–89.
- 12. Abbott PW, Gumusoglu SB, Bittle J, Beversdorf DQ, Stevens HE. Prenatal stress and genetic risk: How
- prenatal stress interacts with genetics to alter risk for psychiatric illness. Psychoneuroendocrinology. 2018;90:9–
- 618 21.
- 619 13. Fine R, Zhang J, Stevens HE. Prenatal stress and inhibitory neuron systems: implications for
- neuropsychiatric disorders. Mol Psychiatry. 2014;19:641–51.
- 14. Croen LA, Qian Y, Ashwood P, Zerbo O, Schendel D, Pinto-Martin J, et al. Infection and Fever in
- 622 Pregnancy and Autism Spectrum Disorders: Findings from the Study to Explore Early Development. Autism
- 623 Res. 2019;12:1551–61.
- 624 15. Kuzniewicz MW, Wi S, Oian Y, Walsh EM, Armstrong MA, Croen LA. Prevalence and Neonatal Factors
- Associated with Autism Spectrum Disorders in Preterm Infants. J Pediatr. 2014;164:20–5.
- 626 16. Apgar V. A proposal for a new method of evaluation of the newborn infant. Curr Res Anesth Analg.
- 627 1953;32:260–7.
- 628 17. Modabbernia A, Sandin S, Gross R, Leonard H, Gissler M, Parner ET, et al. Appar score and risk of autism.
- 629 Eur J Epidemiol. 2019;34:105–14.
- 630 18. Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in "low-functioning" autistic
- children: a pilot study. Biol Psychiatry. 1999;46:420–4.
- 632 19. Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental
- 633 delays or typical development. J Autism Dev Disord. 2014;44:1117–27.
- 634 20. Krajmalnik-Brown R, Lozupone C, Kang D-W, Adams JB. Gut bacteria in children with autism spectrum
- disorders: challenges and promise of studying how a complex community influences a complex disease. Microb
- 636 Ecol Health Dis. 2015;26.

- 21. White JF. Intestinal pathophysiology in autism. Exp Biol Med Maywood NJ. 2003;228:639–49.
- 638 22. Cerdó T, Diéguez E, Campoy C. Early nutrition and gut microbiome: interrelationship between bacterial
- 639 metabolism, immune system, brain structure, and neurodevelopment. Am J Physiol-Endocrinol Metab.
- 640 2019;317:E617-30.
- 641 23. Wang S, Harvey L, Martin R, van der Beek EM, Knol J, Cryan JF, et al. Targeting the gut microbiota to
- influence brain development and function in early life. Neurosci Biobehav Rev. 2018;95:191–201.
- 24. De Angelis M, Francavilla R, Piccolo M, De Giacomo A, Gobbetti M. Autism spectrum disorders and
- intestinal microbiota. Gut Microbes. 2015;6:207–13.
- 645 25. Sharon G, Cruz NJ, Kang D-W, Gandal MJ, Wang B, Kim Y-M, et al. Human Gut Microbiota from Autism
- 646 Spectrum Disorder Promote Behavioral Symptoms in Mice. Cell. 2019;177:1600-1618.e17.
- 647 26. Kelly RS, Boulin A, Laranjo N, Lee-Sarwar K, Chu SH, Yadama AP, et al. Metabolomics and
- 648 Communication Skills Development in Children; Evidence from the Ages and Stages Questionnaire.
- 649 Metabolites. 2019;9:42.
- 650 27. Sgritta M, Dooling SW, Buffington SA, Momin EN, Francis MB, Britton RA, et al. Mechanisms Underlying
- Microbial-Mediated Changes in Social Behavior in Mouse Models of Autism Spectrum Disorder. Neuron.
- 652 2019;101:246-259.e6.
- 28. Adams JB, Borody TJ, Kang D-W, Khoruts A, Krajmalnik-Brown R, Sadowsky MJ. Microbiota transplant
- therapy and autism: lessons for the clinic. Expert Rev Gastroenterol Hepatol. 2019;13:1033–7.
- 29. Adams JB, Vargason T, Kang D-W, Krajmalnik-Brown R, Hahn J. Multivariate Analysis of Plasma
- Metabolites in Children with Autism Spectrum Disorder and Gastrointestinal Symptoms Before and After
- Microbiota Transfer Therapy. Processes. 2019;7:806.
- 30. Borre YE, O'Keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental
- windows: implications for brain disorders. Trends Mol Med. 2014;20:509–18.
- 31. Magistris L de, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, et al. Alterations of the Intestinal
- Barrier in Patients With Autism Spectrum Disorders and in Their First-degree Relatives. J Pediatr Gastroenterol
- 662 Nutr. 2010;51:418–24.
- 663 32. Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma Amino Acid Levels in Children with Autism and
- Their Families. J Autism Dev Disord. 2003;33:93–7.
- 33. Evans C, Dunstan RH, Rothkirch T, Roberts TK, Reichelt KL, Cosford R, et al. Altered amino acid excretion
- in children with autism. Nutr Neurosci. 2008;11:9–17.
- 34. De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serrazzanetti DI, et al. Fecal Microbiota
- and Metabolome of Children with Autism and Pervasive Developmental Disorder Not Otherwise Specified. Plos
- 669 One. 2013;8:e76993.
- 670 35. Kang D-W, Ilhan ZE, Isern NG, Hoyt DW, Howsmon DP, Shaffer M, et al. Differences in fecal microbial
- 671 metabolites and microbiota of children with autism spectrum disorders. Anaerobe. 2018;49:121–31.
- 672 36. Naushad SM, Jain JMN, Prasad CK, Naik U, Akella RRD. Autistic children exhibit distinct plasma amino
- acid profile. Indian J Biochem Biophys. 2013;50:474–8.

- 37. Barone R, Alaimo S, Messina M, Pulvirenti A, Bastin J, Group M-A, et al. A Subset of Patients With Autism
- Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses. Front Psychiatry.
- 676 2018;9.
- 38. Anwar A, Abruzzo PM, Pasha S, Rajpoot K, Bolotta A, Ghezzo A, et al. Advanced glycation endproducts,
- dityrosine and arginine transporter dysfunction in autism a source of biomarkers for clinical diagnosis. Mol
- 679 Autism. 2018;9:3.
- 680 39. Smith AM, King JJ, West PR, Ludwig MA, Donley ELR, Burrier RE, et al. Amino Acid Dysregulation
- Metabotypes: Potential Biomarkers for Diagnosis and Individualized Treatment for Subtypes of Autism
- Spectrum Disorder. Biol Psychiatry. 2019;85:345–54.
- 40. West PR, Amaral DG, Bais P, Smith AM, Egnash LA, Ross ME, et al. Metabolomics as a Tool for
- Discovery of Biomarkers of Autism Spectrum Disorder in the Blood Plasma of Children. PLoS ONE. 2014;9.
- 41. Rangel-Huerta OD, Gomez-Fernández A, de la Torre-Aguilar MJ, Gil A, Perez-Navero JL, Flores-Rojas K,
- et al. Metabolic profiling in children with autism spectrum disorder with and without mental regression:
- preliminary results from a cross-sectional case-control study. Metabolomics Off J Metabolomic Soc. 2019;15:99.
- 42. Bitar T, Mavel S, Emond P, Nadal-Desbarats L, Lefèvre A, Mattar H, et al. Identification of metabolic
- pathway disturbances using multimodal metabolomics in autistic disorders in a Middle Eastern population. J
- 690 Pharm Biomed Anal. 2018;152:57–65.
- 691 43. Delaye J-B, Patin F, Lagrue E, Le Tilly O, Bruno C, Vuillaume M-L, et al. Post hoc analysis of plasma
- amino acid profiles: towards a specific pattern in autism spectrum disorder and intellectual disability. Ann Clin
- 693 Biochem. SAGE Publications; 2018;55:543–52.
- 694 44. Kuwabara H, Yamasue H, Koike S, Inoue H, Kawakubo Y, Kuroda M, et al. Altered Metabolites in the
- 695 Plasma of Autism Spectrum Disorder: A Capillary Electrophoresis Time-of-Flight Mass Spectroscopy Study.
- 696 PLoS ONE. 2013;8.
- 697 45. Retey J. The Urocanase Story: A Novel Role of NAD+ as Electrophile. Arch Biochem Biophys. 1994;314:1–
- 698 16.
- 699 46. Shaw W. Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an
- abnormal phenylalanine metabolite of Clostridia spp. in the gastrointestinal tract, in urine samples from patients
- with autism and schizophrenia. Nutr Neurosci. 2010;13:135–43.
- 702 47. Mayel S, Nadal-Desbarats L, Blasco H, Bonnet-Brilhault F, Barthélémy C, Montigny F, et al. 1H-13C NMR-
- based urine metabolic profiling in autism spectrum disorders. Talanta. 2013;114:95–102.
- 48. Yap IKS, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK. Urinary metabolic phenotyping
- differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res.
- 706 2010;9:2996–3004.
- 49. Ming X, Stein TP, Barnes V, Rhodes N, Guo L. Metabolic perturbance in autism spectrum disorders: a
- metabolomics study. J Proteome Res. 2012;11:5856–62.
- 709 50. Liu A, Zhou W, Qu L, He F, Wang H, Wang Y, et al. Altered Urinary Amino Acids in Children With Autism
- 710 Spectrum Disorders. Front Cell Neurosci. 2019;13.

- 51. Kałużna-Czaplińska J. Noninvasive urinary organic acids test to assess biochemical and nutritional
- 712 individuality in autistic children. Clin Biochem. 2011;44:686–91.
- 52. Lussu M, Noto A, Masili A, Rinaldi AC, Dessì A, Angelis MD, et al. The urinary 1H-NMR metabolomics
- profile of an italian autistic children population and their unaffected siblings. Autism Res. 2017;10:1058–66.
- 715 53. Chen Q, Qiao Y, Xu X, You X, Tao Y. Urine Organic Acids as Potential Biomarkers for Autism-Spectrum
- 716 Disorder in Chinese Children. Front Cell Neurosci. 2019;13.
- 54. Emond P, Mavel S, Aïdoud N, Nadal-Desbarats L, Montigny F, Bonnet-Brilhault F, et al. GC-MS-based
- vrine metabolic profiling of autism spectrum disorders. Anal Bioanal Chem. 2013;405:5291–300.
- 719 55. Noto A, Fanos V, Barberini L, Grapov D, Fattuoni C, Zaffanello M, et al. The urinary metabolomics profile
- of an Italian autistic children population and their unaffected siblings. J Matern Fetal Neonatal Med.
- 721 2014;27:46–52.
- 722 56. Gevi F, Zolla L, Gabriele S, Persico AM. Urinary metabolomics of young Italian autistic children supports
- abnormal tryptophan and purine metabolism. Mol Autism. 2016;7:47.
- 724 57. Wang M, Wan J, Rong H, He F, Wang H, Zhou J, et al. Alterations in Gut Glutamate Metabolism Associated
- with Changes in Gut Microbiota Composition in Children with Autism Spectrum Disorder. mSystems. American
- 726 Society for Microbiology Journals; 2019;4.
- 58. Nørgaard-Pedersen B, Hougaard DM. Storage policies and use of the Danish Newborn Screening Biobank. J
- 728 Inherit Metab Dis. 2007;30:530–6.
- 59. Pedersen CB, Bybjerg-Grauholm J, Pedersen MG, Grove J, Agerbo E, Bækvad-Hansen M, et al. The
- 730 iPSYCH2012 case—cohort sample: new directions for unravelling genetic and environmental architectures of
- severe mental disorders. Mol Psychiatry. 2018;23:6–14.
- 732 60. Vogeser M, Schuster C, Rockwood AL. A proposal to standardize the description of LC-MS-based
- measurement methods in laboratory medicine. Clin Mass Spectrom. 2019;13:36–8.
- 734 61. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, et al. A cross-platform toolkit
- for mass spectrometry and proteomics. Nat Biotechnol. 2012;30:918–20.
- 736 62. Katajamaa M, Miettinen J, Oresic M. MZmine: toolbox for processing and visualization of mass
- 737 spectrometry based molecular profile data. Bioinforma Oxf Engl. 2006;22:634–6.
- 738 63. Pluskal T, Castillo S, Villar-Briones A, Orešič M. MZmine 2: Modular framework for processing,
- visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics. 2010;11:395.
- 740 64. Myers OD, Sumner SJ, Li S, Barnes S, Du X. One Step Forward for Reducing False Positive and False
- 741 Negative Compound Identifications from Mass Spectrometry Metabolomics Data: New Algorithms for
- 742 Constructing Extracted Ion Chromatograms and Detecting Chromatographic Peaks. Anal Chem. 2017;89:8696–
- 743 703.
- 744 65. Nothias LF, Petras D, Schmid R, Dührkop K, Rainer J, Sarvepalli A, et al. Feature-based Molecular
- Networking in the GNPS Analysis Environment. bioRxiv. 2019;812404.

- 746 66. Wang M, Carver JJ, Phelan VV, Sanchez LM, Garg N, Peng Y, et al. Sharing and community curation of
- mass spectrometry data with Global Natural Products Social Molecular Networking, Nat Biotechnol.
- 748 2016;34:828–37.
- 749 67. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment
- 750 for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.
- 751 68. Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA. Untargeted Metabolomics Strategies—
- 752 Challenges and Emerging Directions. J Am Soc Mass Spectrom. 2016;27:1897–905.
- 753 69. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, et al. Proposed minimum reporting
- standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative
- 755 (MSI). Metabolomics. 2007;3:211–21.
- 756 70. Hooft JJJ van der, Wandy J, Barrett MP, Burgess KEV, Rogers S. Topic modeling for untargeted
- substructure exploration in metabolomics. Proc Natl Acad Sci. 2016;113:13738–43.
- 758 71. Silva RR da, Wang M, Nothias L-F, Hooft JJJ van der, Caraballo-Rodríguez AM, Fox E, et al. Propagating
- annotations of molecular networks using in silico fragmentation. PLOS Comput Biol. 2018;14:e1006089.
- 760 72. Mohimani H, Gurevich A, Mikheenko A, Garg N, Nothias L-F, Ninomiya A, et al. Dereplication of peptidic
- natural products through database search of mass spectra. Nat Chem Biol. 2017;13:30–7.
- 762 73. Ernst M, Kang KB, Caraballo-Rodríguez AM, Nothias L-F, Wandy J, Chen C, et al. MolNetEnhancer:
- 763 Enhanced Molecular Networks by Integrating Metabolome Mining and Annotation Tools. Metabolites.
- 764 2019;9:144.
- 765 74. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, et al. ClassyFire: automated
- 766 chemical classification with a comprehensive, computable taxonomy. J Cheminformatics. 2016;8:61.
- 767 75. Wang M, Jarmusch AK, Vargas F, Aksenov AA, Gauglitz JM, Weldon K, et al. Mass spectrometry searches
- 768 using MASST. Nat Biotechnol. 2020;38:23–6.
- 769 76. Böcker S, Dührkop K. Fragmentation trees reloaded. J Cheminformatics. 2016;8:5.
- 770 77. Dührkop K, Shen H, Meusel M, Rousu J, Böcker S. Searching molecular structure databases with tandem
- mass spectra using CSI:FingerID. Proc Natl Acad Sci U S A. 2015;112:12580–5.
- 772 78. Dührkop K, Fleischauer M, Ludwig M, Aksenov AA, Melnik AV, Meusel M, et al. SIRIUS 4: a rapid tool
- for turning tandem mass spectra into metabolite structure information. Nat Methods. 2019;16:299–302.
- 774 79. Shen H, Dührkop K, Böcker S, Rousu J. Metabolite identification through multiple kernel learning on
- fragmentation trees. Bioinforma Oxf Engl. 2014;30:i157-164.
- 776 80. da Silva RR, Vargas F, Ernst M, Nguyen NH, Bolleddu S, del Rosario KK, et al. Computational Removal of
- 777 Undesired Mass Spectral Features Possessing Repeat Units via a Kendrick Mass Filter. J Am Soc Mass
- 778 Spectrom. 2019;30:268–77.
- 779 81. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive,
- scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37:852–7.

- 781 82. Vázquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. EMPeror: a tool for visualizing high-throughput
- 782 microbial community data. GigaScience. 2013;2.
- 783 83. Martino C, Morton JT, Marotz CA, Thompson LR, Tripathi A, Knight R, et al. A Novel Sparse
- Compositional Technique Reveals Microbial Perturbations. mSystems. 2019;4:e00016-19.
- 785 84. Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and
- integrative metabolomics analysis. Nucleic Acids Res. 2018;46:W486–94.
- 787 85. Anderson MJ. A new method for non-parametric multivariate analysis of variance. Austral Ecol.
- 788 2001;26:32–46.
- 789 86. R Core Team. R: a language and environment for statistical computing [Internet]. R Found. Stat. Comput.
- 790 Vienna Austria. 2019 [cited 2019 Nov 21]. Available from: https://www.R-project.org/
- 791 87. Glinton KE, Elsea SH. Untargeted Metabolomics for Autism Spectrum Disorders: Current Status and Future
- 792 Directions. Front Psychiatry. 2019;10.
- 793 88. Mizejewski GJ, Lindau-Shepard B, Pass KA. Newborn screening for autism: in search of candidate
- 794 biomarkers. Biomark Med. 2013;7:247–60.
- 795 89. Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R, et al. Nicotinic receptor abnormalities in the
- cerebellar cortex in autism. Brain J Neurol. 2002;125:1483–95.
- 797 90. Janecka M, Kodesh A, Levine SZ, Lusskin SI, Viktorin A, Rahman R, et al. Association of Autism Spectrum
- 798 Disorder With Prenatal Exposure to Medication Affecting Neurotransmitter Systems. JAMA Psychiatry.
- 799 2018;75:1217–24.
- 800 91. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. The
- 801 Lancet. 2008;371:261–9.
- 92. Gil AM, Duarte D. Biofluid Metabolomics in Preterm Birth Research. Reprod Sci. 2018;25:967–77.
- 93. Ernst M, Rogers S, Lausten-Thomsen U, Bjorkbom A, Laursen SS, Courraud J, et al. Gestational-age-
- dependent development of the neonatal metabolome. medRxiv. Cold Spring Harbor Laboratory Press;
- 805 2020;2020.03.27.20045534.
- 94. Dionisi-Vici C, Deodato F, Roschinger W, Rhead W, Wilcken B. "Classical" organic acidurias, propionic
- 807 aciduria, methylmalonic aciduria and isovaleric aciduria: Long-term outcome and effects of expanded newborn
- screening using tandem mass spectrometry. J Inherit Metab Dis. Springer; 2006;29:383–9.
- 95. Milani C, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, et al. The First Microbial Colonizers of the
- 810 Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota, Microbiol Mol Biol
- 811 Rev MMBR. 2017;81.
- 96. Backhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and Stabilization of
- the Human Gut Microbiome during the First Year of Life. Cell Host Microbe. 2015;17:690–703.
- 97. Rosa PSL, Warner BB, Zhou Y, Weinstock GM, Sodergren E, Hall-Moore CM, et al. Patterned progression
- of bacterial populations in the premature infant gut. Proc Natl Acad Sci. 2014;111:12522–7.

- 98. Wilmanski T, Rappaport N, Earls JC, Magis AT, Manor O, Lovejoy J, et al. Blood metabolome predicts gut
- 817 microbiome α-diversity in humans. Nat Biotechnol. 2019;37:1217–28.
- 99. Meng D, Sommella E, Salviati E, Campiglia P, Ganguli K, Djebali K, et al. Indole-3-lactic acid, a metabolite
- of tryptophan, secreted by Bifidobacterium longum subspecies infantis is anti-inflammatory in the immature
- intestine. Pediatr Res. Nature Publishing Group; 2020;1–9.
- 821 100. Laursen MF, Sakanaka M, Burg N von, Andersen D, Mörbe U, Rivollier A, et al. Breastmilk-promoted
- bifidobacteria produce aromatic lactic acids in the infant gut. bioRxiv. Cold Spring Harbor Laboratory;
- 823 2020;2020.01.22.914994.
- 824 101. Keller MC, Fredrickson BL, Ybarra O, Cote S, Johnson K, Mikels J, et al. A warm heart and a clear head -
- The contingent effects of weather on mood and cognition. Psychol Sci. Blackwell Publishing; 2005;16:724–31.
- 826 102. D'Amato G, Holgate ST, Pawankar R, Ledford DK, Cecchi L, Al-Ahmad M, et al. Meteorological
- 827 conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the
- World Allergy Organization. World Allergy Organ J. Elsevier; 2015;8:UNSP 25.
- 829 103. Ruoppolo M, Scolamiero E, Caterino M, Mirisola V, Franconi F, Campesi I. Female and male human
- babies have distinct blood metabolomic patterns. Mol Biosyst. 2015;11:2483–92.
- 831 104. Diaz SO, Pinto J, Barros AS, Morais E, Duarte D, Negrão F, et al. Newborn Urinary Metabolic Signatures
- of Prematurity and Other Disorders: A Case Control Study. J Proteome Res. 2016;15:311–25.
- 833 105. Challis J, Newnham J, Petraglia F, Yeganegi M, Bocking A. Fetal sex and preterm birth. Placenta.
- 834 2013;34:95–9.
- 835 106. Wilkin TJ, Murphy MJ. The gender insulin hypothesis: why girls are born lighter than boys, and the
- implications for insulin resistance. Int J Obes. 2006;30:1056–61.
- 107. Wehrens R, Hageman JosA, van Eeuwijk F, Kooke R, Flood PJ, Wijnker E, et al. Improved batch
- correction in untargeted MS-based metabolomics. Metabolomics. 2016;12.
- 839 108. Petrick L, Edmands W, Schiffman C, Grigoryan H, Perttula K, Yano Y, et al. An untargeted metabolomics
- method for archived newborn dried blood spots in epidemiologic studies. Metabolomics Off J Metabolomic Soc.
- 841 2017;13.

- 842 109. Folketinget. Bekendtgørelse af lov om videnskabsetisk behandling af sundhedsvidenskabelige
- forskningsprojekter (The Danish Parliament. Order of law on scientific treatment of health scientific research
- projects) [Internet]. retsinformation.dk. 2017 [cited 2019 Oct 28]. Available from:
- https://www.retsinformation.dk/Forms/r0710.aspx?id=192671

847 Tables848 Table 1. Subjects characteristics

	All subjects n = 74						After outlier removal n = 68						
		cases			controls			cases			controls		
Age at 1 st Jan. 2006 (months, median (range))	7.6	(0.8-11.6)		7.6	(0.8-11.6)		7.3	(0.8-11.6)		7.5	(0.8-11.6)		
Gender (girls / boys)		8 / 29			8 / 29			7 / 25			8 / 28		
Classification of cases (ICD10) ¹													
- F84.0 Childhood autism		17			-			15			-		
- F84.1 Atypical autism		7			-			6			-		
- F84.5 Asperger syndrome		4			-			3			-		
- F84.8 Other pervasive		4			-			4			-		
developmental disorders													
- F84.9 Unspecified pervasive		11			-			10			-		
developmental disorders													
Gestational age (weeks, median (range), NA)	40	(33-42)	5	39	(30-42)	2	40	(33-41)	4	39	(30-42)	2	
Birthweight (g, median (range), NA)	3500	(2210-4880)	1	3480	(977-4850)	2	3498	(2210-4880)	0	3490	(977-4850)	2	
Age at sampling (days, median (range), NA)	6	(3-9)	3	6	(4-10)	3	6	(3-9)	2	6	(4-10)	3	
Age of mother at birth (years, median (range))	31.7	(20.8-41.5)		31.7	(18.3-41.2)		32.3	(20.8-41.5)		31.8	(18.3-41.2)		

849 ¹ ICD10 classification [2]

851

852

853

More details are provided in Additional file 6.

Table 2. Differentially abundant features in univariate analyses without FDR correction (p<0.01) and/or with high fold-change meeting inspection criteria

Putative annotation of relevant	Annotation level ¹	m/z	RT ID (min)		p-value t-test		p-value Wilcoxon rank-sum test		FC ²	Network connections ³
compounds					without FDR correction	with FDR correction	without FDR correction	with FDR correction		
Methacholine C ₈ H ₁₈ NO ₂ ⁺	24	160.13315	0.45	159	0.0021	0.9174	0.0031	0.9434	1.25	connected to 1853 (-0.036 m/z)
SIRIUS 99.96%: C ₁₁ H ₂₂ N ₂ O ₃ (M+H+)	4	231.17005	2.78	5593	0.0072	0.9174	0.0138	0.9434	1.46	Single node
SIRIUS 7.12%: $C_{36}H_{63}N_{21}O_{14}$ $(M+H+)$	4	1014.48923	6.64	8605	0.0414	0.9174	0.0179	0.9434	0.42	Single node

856 Annotation level of confidence according to the Metabolomics Standards Initiative (i.e. putative annotation) [68,69].

857 ² FC: Fold-change (case/control)

862

863

864

865

866

867

- 858 ³ Network connections in GNPS feature-based molecular network.
- 4 Source of annotation mzCloud (89.9% score). See its mass spectrum in Additional file 10.
- Inspection criteria: peak integration or shape quality, initial missing values, single values plot, presence and consistence in replicated
- pool injections, annotation or connection to contaminants. For details see Additional file 7.

868 Table 3. Compounds reported in the literature three or more times as being associated with ASD

Compound name	Annot- ation level ¹	Raw formula	<i>m/z</i> [M+H]+	RT (min)	Feature ID (MZmine 2.41)	Detected by Compound Discoverer 2.1	HMDB ID	Literature reference
Arginine	1	C6H14N4O2	175.11895	0.35	1450	ND	HMDB0000517	[38,44,50]
Aspartic acid	1	C4H7NO4	134.04478	0.41	1073	ND	HMDB0000191	[34,35,40,41,50,57]
Citric acid	4	C6H8O7	193.03428	0.35	1776	yes	HMDB0000094	[40,42,51]
Creatine	2	C4H9N3O2	132.07675	0.40	16	yes	HMDB0000064	[42,47,52]
Creatinine	2	C4H7N3O	114.06619	0.40	281	yes	HMDB0000562	[40,50,52,53]
Decanoylcarnitine	1	C17H33NO4	316.24823	6.00	3633	yes	HMDB0000651	[37,41,57]
Glutamic acid	1	C5H9NO4	148.06043	0.38	136	yes	HMDB0000148	[34,35,38,40–43,52]
Glutamine	2	C5H10N2O3	147.07642	0.40	107	yes	HMDB0000641	[35,38,39]
Glycine	3	C2H5NO2	76.03930	0.38	1177	ND	HMDB0000123	[34,39,43,47,49,52]
Glycolic acid	-	C2H4O3	77.02332	-	ND	ND	HMDB0000115	[53–55]
Hippuric acid	2	C9H9N1O3	180.06552	3.04	5174	ND	HMDB0000714	[48,51,52,54]
Histidine	2	C6H9N3O2	156.07675	0.32	342	yes	HMDB0000177	[34,49,56]
Lactic acid	-	C3H6O3	91.03897	-	ND	ND	HMDB0000190	[35,44,52]
p-cresol	-	C7H8O1	109.06479	-	ND	ND	HMDB0001858	[34,35,53,56]
Phenylalanine	1	C9H11NO2	166.08625	1.70	594+5370+287	yes	HMDB0000159	[34,56,57]
Serine	2	C3H7NO3	106.04987	0.40	437	ND	HMDB0000187	[34,40,42,43,49]
Succinic acid	-	C4H6O4	119.03388	-	ND	ND	HMDB0000254	[40,47,48,54]
Taurine	3	C2H7NO3S	126.02194	0.43	428	ND	HMDB0000251	[25,44,47–49,52]
Threonine	2	C4H9NO3	120.06552	0.40	476	ND	HMDB0000167	[38,42,49,50]
Tryptophan	2	C11H12N2O2	205.09715	2.53	164	yes	HMDB0000929	[38,41,52,55,56]
Tyrosine	1	C9H11NO3	182.08117	0.72	58	yes	HMDB0000158	[35,42,57]
Valine	2	C5H11NO2	118.08625	0.42	ND	yes	HMDB0000883	[34,39,52]

ND: not detected

- Annotation level of confidence according to the Metabolomics Standards Initiative (i.e. putative annotation) [68,69].
- When the [M+H]+ adduct could not be found (+/- 5 ppm), common adducts were searched including [M+Na]+, [M+K]+, [M+2H]2+,
- 872 $[M+H-H_2O]+.$
- 873 See full list of compounds considered and more details in Additional file 11.

Figure 1. Feature-based molecular network displaying the 15 predominant putative chemical classes and their subclasses

Nodes represent mass spectral features and are used as a proxy for a metabolite. Connected nodes represent high tandem mass spectral similarity, and thus high chemical structural similarity. The thickness of the grey edges connecting nodes varies according to the cosine score representing to what extent two connected metabolites are chemically similar (based on MS2 spectra, from 0.7: less similar and thin edge to 1.0: identical and thick edge).

The name of annotated metabolites (levels 1 and 2), details on chemical classes with fewer than 4 metabolites (absent on this figure), chemical classification scores [73], all unknowns, and group intensities for all features (average, standard deviations) are detailed in Additional file 7.

See Figure_1.pdf





Figure 2. Network of molecular features putatively annotated as bile acids with average group intensities, fold change values, mass differences and cosine scores displayed.

Molecular family #75 is composed of eight bile acid structural analogues (see details in Additional File 7). Coloring according to the fold change values makes it easier to spot the families with differential abundance in cases vs. controls. Displaying average intensities for the three groups (cases, controls, paper blanks) allows for a quick control of the noise (paper blanks, here no noise detected) and confirmation of fold change. On edges, while the thickness of the connection represents to what extent two metabolites are chemically similar, the mass difference is essential to support annotation as it translates into how molecules differ from one another (e.g. water loss, conjugation, adducts, etc.).

See Figure 2.pdf



- 898 Figure 3. Bray-Curtis principal coordinates analysis of the 68 samples after outlier removal.
- 899 Each sphere represents one sample. Axes are principal components 1 (x) and 3 (y) explaining 18.48%
- and 8.79% of the variability in the data, respectively. The four replicated pool injections cluster
- 901 satisfactorily.
- a) Coloring reflects the type of samples, i.e. cases, controls and four replicated pool injections. No clear
- distinction between cases and controls can be observed (PERMANOVA Adonis $R^2 = 0.014$, P-value =
- 904 0.777).
- b) Coloring reflects the month of birth for the 68 samples as well as the four replicated pool injections.
- Samples collected in the winter (dark purple and yellow, extremities of the colors scale) are positioned
- away from the samples collected in summer (green and turquoise, middle of the color scale). 26.2% of
- the variation in the data can be explained by month of birth (Adonis $R^2 = 0.262$, P-value = 0.001)
- 909 See Additional file 8 for detailed values with and without FDR correction and for other distance
- 910 matrices.

911 See Figure_3ab.pdf




Figure 4. PERMANOVAs of the four tested distance matrices showing how much of the variation
(Adonis R²) is explained by a metadata variable.


P-values include FDR correction. A star is present when the corrected p-values was <0.05.

All exact values are available in Additional file 8 and detailed metadata (subject characteristics) are available in Table 1 and Additional file 6.

See Figure_4.pdf

919

920



921 **Additional files** 922 Additional file 1: 923 Standardized reporting of untargeted metabolomics LC-MS/MS method according to [60] containing 924 the list of internal standards from the Neobase Non-derivatized MSMS kit and their concentration in 925 the extraction buffer 926 See .xlsx 927 928 Additional file 2: 929 MZmine batch .xml file used to preprocess the raw data 930 See .xml 931 932 Additional file 3: 933 Compound Discoverer 2.1 preprocessing workflow settings 934 See .pdf 935 936 Additional file 4ab: 937 PEG (4a) and PPG (4b) filtering scripts using the Kendrick Mass filter according to [80] 938 See the two .ipynb 939 Can be opened using https://jupyter.org/ 940 941 Additional file 5: 942 Targeted analysis of outliers using TraceFinder (IS and unlabeled homologs) and heatmap of 943 untargeted analysis 944 See .pdf 945 946 Additional file 6: 947 Subjects characteristics in details 948 See .xlsx 949 950 Additional file 7:

951 All features including annotated compounds. Out of the 4360 features detected, 150 could be annotated 952 by GNPS library matching (annotation level 2) or in-house Trace Finder library (annotation level 1) 953 and an additional 859 by MolNetEnhancer (annotation level 3). 954 See .xlsx 955 Additional file 8: 956 957 PERMANOVAs Adonis R² values and p-values calculated with (74 samples) and without (68 samples) 958 outliers 959 See .xlsx 960 961 Additional file 9: Full list of compounds with t-test p value <0.01 without FDR correction and/or with Wilcoxon rank-962 963 sum test p value <0.01 without FDR correction and/or case/control fold change value <0.5 or >2. 964 See .xlsx 965 966 Additional file 10: Fragmentation profiles of the two unknown features to be monitored in future 967 studies as well as methacholine as shown in Table 2. 968 See .pdf 969 970 Additional file 11: Full list of compounds reported in the literature as involved in ASD and considered 971 in this study. 972 See .xlsx 973